The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
AMSC-derived exosomes alleviate lipopolysaccharide/d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages
Open accessAbstract
Background Mesenchymal stem cell (MSC)-derived exosome administration has been considered as a novel cell-free therapy for liver diseases through cell-cell communication. This study was aimed to determine the effects and mechanisms of AMSC-derived exosomes (AMSC-Exo) for acute liver failure (ALF) treatment. Methods AMSC-Exo were intravenously administrated into the mice immediately after lipopolysaccharide and D-galactosamine (LPS/GalN)-exposure and their effects were evaluated by liver histological and serum biochemical analysis. To elucidate its mechanisms in ALF therapy, the expression levels of miRNAs and inflammasome-related genes in macrophages were evaluated by qPCR and Western blot analysis, respectively. The exosomes from miR-17-knockdowned AMSCs (AMSC-Exo miR-17-KD ) were used for further determine the role of miR-17 in AMSC-Exo-based therapy. Findings AMSC-Exo administration significantly ameliorated ALF as determined by reduced serum alanine aminotransferase and aspartate aminotransferase levels and hepatic inflammasome activation. Further experiments revealed that AMSC-Exo were colocalized with hepatic macrophages and could reduce inflammatory factor secretion by suppressing inflammasome activation in macrophages. Moreover, miR-17, which can suppress NLRP3 inflammasome activation by targeting TXNIP, was abundant in AMSC-Exo cargo. While, the therapeutic effects of AMSC-Exo miR-17-KD on ALF were significantly abolished as they could not effectively suppress TXNIP expression and consequent inflammasome activation in vitro and in vivo . Interpretation: Exosome-shuttled miR-17 plays an essential role in AMSC-Exo therapy for ALF by targeting TXNIP and suppressing inflammasome activation in hepatic macrophages. AMSC-Exo-based therapy may present as a promising approach for TXNIP/NLRP3 inflammasome-related inflammatory liver diseases. Fund Key R&D projects of Zhejiang province (2018C03019) and National Natural Science Fund (81470851 and 81500616).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanism and Regulation of NLRP3 Inflammasome Activation
He, Y., Hara, H., & Núñez, G. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.09.002 · Cited by 2,759
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Ju, C., & Tacke, F. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.104 · Cited by 554
Tan, C. Y., Lai, R. C., Wong, W., Dan, Y. Y., Lim, S.-K., & Ho, H. K. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt465 · Cited by 548
The microRNA regulatory landscape of MSC-derived exosomes: a systems view
Ferguson, S. W., Wang, J., Lee, C. J., Liu, M., Neelamegham, S., Canty, J. M., & Nguyen, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-19581-x · Cited by 360
Role of inflammatory response in liver diseases: Therapeutic strategies
Campo, J. A. D., Gallego, P., & Grande, L. (2018) · World Journal of Hepatology · doi:10.4254/wjh.v10.i1.1 · Cited by 348
Cited by
Bian, D., Wu, Y., Song, G., Azizi, R., & Zamani, A. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02697-9 · Cited by 370
Hu, Q., Lyon, C. J., Fletcher, J. K., Tang, W., Wan, M., & Hu, T. Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.014 · Cited by 309
Xu, G., Jin, J., Fu, Z., Wang, G., Lei, X., Xu, J., & Wang, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02312-w · Cited by 269
Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?
Trigo, C. M., Rodrigues, J. S., Camões, S. P., Solá, S., & Miranda, J. P. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.004 · Cited by 252
Psaraki, A., Ntari, L., Karakostas, C., Korrou‐Karava, D., & Roubelakis, M. G. (2022) · Hepatology · doi:10.1002/hep.32129 · Cited by 145
Metadata
- Authors
- Liu, Y., Lou, G., Li, A., Zhang, T., Qi, J., Ye, D., Zheng, M., & Chen, Z.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 36
- Pages
- 140-150
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2891735879
- Cited by
- 217
- References
- 6
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AMSC-derived exosomes alleviate lipopolysaccharide/d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages. https://app.cochat.ai/papers/10.1016/j.ebiom.2018.08.054
- The paper
- Liu, Y., Lou, G., Li, A., Zhang, T., Qi, J., Ye, D., Zheng, M., & Chen, Z. (2018). AMSC-derived exosomes alleviate lipopolysaccharide/d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages. EBioMedicine. https://doi.org/10.1016/j.ebiom.2018.08.054
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.